Marshall Wace North America L.P. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
Marshall Wace North America L.P. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2021$18,616,000
+49.6%
206,420
+58.1%
0.08%
+49.1%
Q2 2021$12,448,000
+1641.0%
130,561
+2430.3%
0.05%
+1666.7%
Q4 2020$715,000
+45.9%
5,160
-19.7%
0.00%
+50.0%
Q3 2018$490,000
-16.5%
6,424
-49.2%
0.00%
-33.3%
Q4 2017$587,00012,6520.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 727,426$25,932,7374.72%
RTW INVESTMENTS, LP 5,405,089$192,691,4234.07%
First Light Asset Management, LLC 1,125,032$40,107,3913.81%
CHI Advisors LLC 215,000$7,664,7503.04%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 250,052$8,914,3543.00%
SPHERA FUNDS MANAGEMENT LTD. 259,135$9,238,1631.68%
Rock Springs Capital Management LP 1,476,441$52,635,1221.41%
SUVRETTA CAPITAL MANAGEMENT, LLC 679,459$24,222,7131.31%
Privium Fund Management B.V. 115,241$4,108,3411.22%
SECTOR GAMMA AS 115,166$4,105,6681.05%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders